U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H29NO3.C4H4O4
Molecular Weight 531.5962
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of ZAMIFENACIN FUMARATE

SMILES

OC(=O)\C=C\C(O)=O.C(CC1=CC2=C(OCO2)C=C1)N3CCC[C@H](C3)OC(C4=CC=CC=C4)C5=CC=CC=C5

InChI

InChIKey=PMHKTAIGYOVZEZ-ZHWJIHCSSA-N
InChI=1S/C27H29NO3.C4H4O4/c1-3-8-22(9-4-1)27(23-10-5-2-6-11-23)31-24-12-7-16-28(19-24)17-15-21-13-14-25-26(18-21)30-20-29-25;5-3(6)1-2-4(7)8/h1-6,8-11,13-14,18,24,27H,7,12,15-17,19-20H2;1-2H,(H,5,6)(H,7,8)/b;2-1+/t24-;/m1./s1

HIDE SMILES / InChI
Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE
Molecular Formula C27H29NO3
Molecular Weight 415.5241
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Zamifenacin, also known as UK-76654, a selective muscarinic M3 receptor antagonist, was studied in patients with irritable bowel syndrome (IBS). This drug participated in clinical trials for the IBS phase III in the USA and phase II in the UK, but these studies were discontinued.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Muscarinic acetylcholine receptor M3
160
Target ID: P20309
Gene ID: 1131.0
Gene Symbol: CHRM3
Target Organism: Homo sapiens (Human)
Antagonist
2849
 8.52 null [pKi]
PubMed

PubMed

TitleDatePubMed
In vitro toxicity of zamifenacin (UK-76,654) and metabolites in primary hepatocyte cultures.
1998-09
Zamifenacin (UK-76, 654) a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome.
1997-06
Characterization of the interaction of zamifenacin at muscarinic receptors in vitro.
1995-10-16
Patents

Patents

20050004155
2
JPH07157469A
2

Sample Use Guides

In Vivo Use Guide
single dose of zamifenacin 10 mg or 40 mg on both fasting (30 min) and fed (60 min)
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Mon Mar 31 22:07:28 GMT 2025
Edited
by admin
on Mon Mar 31 22:07:28 GMT 2025
Record UNII
YCS9BM2UNR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
UK-76654-2
Preferred Name English
ZAMIFENACIN FUMARATE
Common Name English
PIPERIDINE, 1-(2-(1,3-BENZODIOXOL-5-YL)ETHYL)-3-(DIPHENYLMETHOXY)-, (3R)-, (2E)-2-BUTENEDIOATE (1:1)
Systematic Name English
(R)-3-(BENZHYDRYLOXY)-1-(2-(BENZO(D)(1,3)DIOXOL-5-YL)ETHYL)PIPERIDINE FUMARATE
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID9049037
Created by admin on Mon Mar 31 22:07:28 GMT 2025 , Edited by admin on Mon Mar 31 22:07:28 GMT 2025
PRIMARY
PUBCHEM
60196362
Created by admin on Mon Mar 31 22:07:28 GMT 2025 , Edited by admin on Mon Mar 31 22:07:28 GMT 2025
PRIMARY
CAS
127308-98-9
Created by admin on Mon Mar 31 22:07:28 GMT 2025 , Edited by admin on Mon Mar 31 22:07:28 GMT 2025
PRIMARY
FDA UNII
YCS9BM2UNR
Created by admin on Mon Mar 31 22:07:28 GMT 2025 , Edited by admin on Mon Mar 31 22:07:28 GMT 2025
PRIMARY
Related Record Type Details
Structure of ZAMIFENACIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966